Your browser doesn't support javascript.
loading
Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).
Fu, Tiancheng; Zuo, Yingying; Zhong, Zhenpeng; Chen, Xuan; Pan, Zhengying.
Afiliación
  • Fu T; State Key Laboratory of Chemical Oncogenomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China.
  • Zuo Y; State Key Laboratory of Chemical Oncogenomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China.
  • Zhong Z; State Key Laboratory of Chemical Oncogenomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China.
  • Chen X; State Key Laboratory of Chemical Oncogenomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China.
  • Pan Z; State Key Laboratory of Chemical Oncogenomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China. Electronic address: panzy@pkusz.edu.cn.
Eur J Med Chem ; 229: 114051, 2022 Feb 05.
Article en En | MEDLINE | ID: mdl-34952433
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diseño de Fármacos / Familia-src Quinasas / Inhibidores de Proteínas Quinasas Límite: Humans Idioma: En Revista: Eur J Med Chem Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diseño de Fármacos / Familia-src Quinasas / Inhibidores de Proteínas Quinasas Límite: Humans Idioma: En Revista: Eur J Med Chem Año: 2022 Tipo del documento: Article País de afiliación: China